Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Naoko Hata Sugi
Observed names:
N.H Sugi,
Naoko H. Sugi
Institution:
Eisai (Japan)
Observed institution:
Eisai (Japan)
ORCID:
0000-0002-9561-6531
Observed ORCID:
0000-0002-9561-6531
OpenAlex ID:
A5074452617
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
2017
·
Taisuke Uehara
, Yukinori Minoshima
, et al.
·
Nature Chemical Biology
·
413
Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle
1999
·
Takashi Owa
, Hiroshi Yoshino
, et al.
·
Journal of Medicinal Chemistry
·
339
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
2013
·
Kiyoshi Okamoto
, Kotaro Kodama
, et al.
·
Cancer Letters
·
311
PDF
Biological validation that SF3b is a target of the antitumor macrolide pladienolide
2011
·
Akira Yokoi
, Yoshihiko Kotake
, et al.
·
FEBS Journal
·
195
PDF
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo
2001
·
Y Ozawa
, N.H Sugi
, et al.
·
European Journal of Cancer
·
143
Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
2002
·
Yasuhiro Funahashi
, Naoko Hata Sugi
, et al.
·
PubMed
·
123
An Angiogenesis Inhibitor E7820 Shows Broad-Spectrum Tumor Growth Inhibition in a Xenograft Model
2004
·
Taro Semba
, Yasuhiro Funahashi
, et al.
·
Clinical Cancer Research
·
80
PDF
Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis.
2002
·
Akira Yokoi
, Junro Kuromitsu
, et al.
·
PubMed
·
77
A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors
2000
·
Takashi Owa
, Tatsuo Okauchi
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
59
Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking
2015
·
Xingfeng Bao
, Wanjun Zheng
, et al.
·
Cancer Biology & Therapy
·
52
PDF
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
2016
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
·
Molecular Cancer Therapeutics
·
44
PDF
Discovery of a potent and selective Axl inhibitor in preclinical model
2021
·
Satoshi Inoue
, Yoshinobu Yamane
, et al.
·
Bioorganic & Medicinal Chemistry
·
14
Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents
2002
·
Takashi Owa
, Hiroshi Yoshino
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
11
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors
2021
·
Satoshi Inoue
, Yoshinobu Yamane
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
9
A novel antitumor agent ER-35744, targeting G1 phase II Antitumor activities in vitro and in vivo
1996
·
Naoko Hata Sugi
, Yuta Ozawa
, et al.
·
Proceedings of the American Association for Cancer Research Annual Meeting
·
7
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2022
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
·
Molecular Cancer Therapeutics
·
5
Abstract 770: E7090: A potent and selective FGFR inhibitor with activity in multiple FGFR-driven cancer models with distinct mechanisms of activation
2015
·
Saori Watanabe Miyano
, Yuji Yamamoto
, et al.
·
Cancer Research
·
3
Abstract A296: Eribulin mesylate suppresses experimental metastasis in the MX-1 human breast cancer model by reversing phenotypic states between epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET).
2013
·
Taku Yoshida
, Galina Kuznetsov
, et al.
·
Molecular Cancer Therapeutics
·
2
Abstract 1371: Systems biology analysis to identify biomarkers for lenvatinib in the preclinical cancer cell line panels
2015
·
Zoltan Dezso
, Mitsuhiro Ino
, et al.
·
Cancer Research
·
1
Supplementary Figures S1-S7 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2025
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
PDF
Supplementary Table S2 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2025
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
Supplementary Table S5 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2025
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
Supplementary Table S3 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2025
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
Supplementary Table S1 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2025
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
Supplementary Table S4 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
2025
·
Shuntaro Tsukamoto
, Naoko Hata Sugi
, et al.
Show more works
View as search
Works count:
57
Citation count:
1,888
H-index:
12
I10-index:
13
Year
Topic
Type